

FOI 8388 - intra-vitreous injections or implants – Q2

Please provide the number of injections/implants by eye condition for the four-month period from September to December 2024:

Number of Injections/Implants: September to December 2024:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	660	40	338
Bevacizumab	<5	0	0
Dexamethasone	0	6	<5
Faricimab	622	226	18
Ranibizumab - Lucentis	<5	0	0
Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	0	0	0